Figure 3.

Association between response to treatment and clinical characteristics and biomarkers

Co-occurring mutations were most commonly detected in TP53, NF1, ARID1A, MET, PDGFRA, and RB1. The genes most frequently co-amplified with MET were CDK6, EGFR, BRAF, CCNE1, and PDGFRA. ADC, adenocarcinoma; BOR, best overall response; CR, complete response; ctDNA, circulating tumor DNA; DOR, duration of response; IRC, independent review committee; NE, not evaluable; NOS, not otherwise specified; PD, progressive disease; PR, partial response; Q3, SCC, squamous cell carcinoma; SD, stable disease; SOLD, sum of target lesion diameters.